The impact of bone loss in women with endometriosis.
Low peak adult bone mass in a premenopausal woman puts her at increased risk for osteoporosis postmenopausally. Episodes of hypo-estrogenism premenopausally are associated with loss of bone density. This is seen with gonadotropin-releasing hormone agonist therapy for endometriosis, and thus prolonged or repeated courses of such treatment may increase the future risk of osteoporosis. Danazol and related compounds do not result in any bone loss but may have certain metabolic disadvantages.
Stevenson
J C
JC
Wynn Department of Metabolic Medicine, National Heart and Lung Institute, London, UK.
D000328:Adult; D015519:Bone Density / Q000187:drug effects* / Q000502:physiology; D003613:Danazol / Q000627:therapeutic use*; D004715:Endometriosis / Q000188:drug therapy*; D004967:Estrogens / Q000172:deficiency; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000009:adverse effects* / Q000819:agonists; D006801:Humans; D010024:Osteoporosis / Q000209:etiology* / Q000503:physiopathology; D017697:Premenopause
D004967:Estrogens; D007987:Gonadotropin-Releasing Hormone; D003613:Danazol